Department of Health
and Human Services (HHS)
and Human Services (HHS)
April 21, 2021
NOT-OD-21-087 - Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being
National Cancer Institute (NCI)
The purpose of this Notice is to revise NOT-OD-21-087 "Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being".
The following section of NOT-OD-21-087 is being revised to include PAR-21-190 "Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Required)":
Purpose, IC Specific Application and Submission Information
Currently reads:
National Cancer Institute (NCI)
NCI’s FOAs for this NOSI include the following or their subsequent reissued equivalents:
|
Activity Code |
FOA |
First Available Application Due Date |
|
R01 |
PAR-21-035- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) |
June 5, 2021 |
|
R01 |
PAR-21-033– NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) |
June 5, 2021 |
|
R21 |
PAR-19-309- Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) |
June 16, 2021 |
|
R03 |
PAR-20-052- NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) |
June 24, 2021 |
|
R15 |
PAR-19-135- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) |
June 25, 2021 |
|
R15 |
PAR-19-133- Academic Research Enhancement Award for Undergraduate- Focused Institutions (R15 - Clinical Trial Required) |
June 25, 2021 |
Should now read (in italics):
NCI’s FOAs for this NOSI include the following or their subsequent reissued equivalents:
|
Activity Code |
FOA |
First Available Application Due Date |
|
PAR-21-190 – Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Required) |
Nov 8, 2021 |
|
|
R01 |
PAR-21-035- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) |
June 5, 2021 |
|
R01 |
PAR-21-033– NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) |
June 5, 2021 |
|
R21 |
PAR-19-309- Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) |
June 16, 2021 |
|
R03 |
PAR-20-052- NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) |
June 24, 2021 |
|
R15 |
PAR-19-135- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) |
June 25, 2021 |
|
R15 |
PAR-19-133- Academic Research Enhancement Award for Undergraduate- Focused Institutions (R15 - Clinical Trial Required) |
June 25, 2021 |
All other aspects of NOT-OD-21-087 remain unchanged.
Frank Perna, Ed.D., Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6782
Email: pernafm@mail.nih.gov